Tin tức & Cập nhật

MONARCH 3 final OS data support abemaciclib-NSAI for HR+/HER2- advanced breast cancer

18 Dec 2023 bởi

In the final overall survival (OS) analysis of the phase III MONARCH 3 trial, the combination of the CDK 4/6 inhibitor abemaciclib and a nonsteroidal aromatase inhibitor (NSAI) continued to show clinically meaningful signals as first-line (1L) treatment for HR+/HER2- advanced breast cancer.

MONARCH 3 final OS data support abemaciclib-NSAI for HR+/HER2- advanced breast cancer

18 Dec 2023

Original New Drug Application Approvals by US FDA (01-15 December 2023)

18 Dec 2023

New drug applications approved by US FDA as of 01-15 December 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01-15 December 2023)

18 Dec 2023

Zonulin a promising biomarker for preclinical coeliac disease screening

18 Dec 2023

Zonulin levels appear to substantially increase in the months leading up to a diagnosis of coeliac disease, as reported in a study. Additionally, exposure to a greater number of antibiotic courses contribute to an increase in zonulin levels in individuals with coeliac disease, highlighting a potential role for the marker in preclinical screening.

Zonulin a promising biomarker for preclinical coeliac disease screening

18 Dec 2023

AI-guided stethoscope helps detect cardiomyopathy during pregnancy

18 Dec 2023 bởi

A screening programme that incorporates artificial intelligence (AI)-guided digital stethoscope improves clinicians’ ability to detect peripartum cardiomyopathy in the Nigerian SPEC-AI trial.

AI-guided stethoscope helps detect cardiomyopathy during pregnancy

18 Dec 2023

$Golidocitinib shows promise in relapsed or refractory peripheral T-cell lymphoma$

Golidocitinib shows promise in relapsed or refractory peripheral T-cell lymphoma

17 Dec 2023

The investigational selective JAK1 tyrosine-kinase inhibitor golidocitinib demonstrates a favourable benefit–risk profile in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma, according to the phase II JACKPOT8 Part B study.

Golidocitinib shows promise in relapsed or refractory peripheral T-cell lymphoma

17 Dec 2023

Albuminuria reduction accounts for treatment effect on CKD outcomes in T2D

17 Dec 2023

Early albuminuria reduction with finerenone in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) is responsible for a huge proportion of the treatment effect against CKD progression and facilitates a modest amount of the effect against cardiovascular outcomes, reports a study.

Albuminuria reduction accounts for treatment effect on CKD outcomes in T2D

17 Dec 2023

Remimazolam shows promise in procedural sedation

17 Dec 2023

Procedural sedation with remimazolam delivers effective sedation without adversely affecting haemodynamics and respirations or lingering drowsiness, as reported in a study.

Remimazolam shows promise in procedural sedation

17 Dec 2023

Long-term voxelotor use increases Hb, reduces haemolysis markers in patients with SCD

17 Dec 2023 bởi

Long-term treatment with voxelotor 1,500 mg led to sustained improvements in haemoglobin (Hb) levels and reductions in clinical markers of haemolysis among patients with sickle cell disease (SCD), according to an updated interim analysis of the HOPE open-label extension (OLE) study presented at ASH 2023.

Long-term voxelotor use increases Hb, reduces haemolysis markers in patients with SCD

17 Dec 2023

$Supplementation does little to reduce fractures in schoolchildren with vitamin D deficiency$

Supplementation does little to reduce fractures in schoolchildren with vitamin D deficiency

16 Dec 2023

Among schoolchildren with a high baseline prevalence of vitamin D deficiency, oral supplementation with vitamin D for 3 years is safe but falls short of reducing the risk of fracture, according to a study.

Supplementation does little to reduce fractures in schoolchildren with vitamin D deficiency

16 Dec 2023

Weight loss with tirzepatide reversed after stopping treatment

16 Dec 2023 bởi

For individuals with overweight or obesity who are taking tirzepatide for weight management, continued treatment results in sustained and even augmented weight loss. When treatment is stopped, however, the achieved weight loss is substantially reversed.

Weight loss with tirzepatide reversed after stopping treatment

16 Dec 2023

Tin tức & Cập nhật

Lọc theo Chuyên ngành:

Chuyên ngành:

MONARCH 3 final OS data support abemaciclib-NSAI for HR+/HER2- advanced breast cancer

MONARCH 3 final OS data support abemaciclib-NSAI for HR+/HER2- advanced breast cancer

Original New Drug Application Approvals by US FDA (01-15 December 2023)

Original New Drug Application Approvals by US FDA (01-15 December 2023)

Zonulin a promising biomarker for preclinical coeliac disease screening

Zonulin a promising biomarker for preclinical coeliac disease screening

AI-guided stethoscope helps detect cardiomyopathy during pregnancy

AI-guided stethoscope helps detect cardiomyopathy during pregnancy

Golidocitinib shows promise in relapsed or refractory peripheral T-cell lymphoma

Golidocitinib shows promise in relapsed or refractory peripheral T-cell lymphoma

Albuminuria reduction accounts for treatment effect on CKD outcomes in T2D

Albuminuria reduction accounts for treatment effect on CKD outcomes in T2D

Remimazolam shows promise in procedural sedation

Remimazolam shows promise in procedural sedation

Long-term voxelotor use increases Hb, reduces haemolysis markers in patients with SCD

Long-term voxelotor use increases Hb, reduces haemolysis markers in patients with SCD

Supplementation does little to reduce fractures in schoolchildren with vitamin D deficiency

Supplementation does little to reduce fractures in schoolchildren with vitamin D deficiency

Weight loss with tirzepatide reversed after stopping treatment

Weight loss with tirzepatide reversed after stopping treatment